Cyclic (YCDGFYACYMDV)

• Description :

  Cyclic (YCDGFYACYMDV) is a HER2 signaling pathway inhibitor with anti-cancer activity. This compound self-assembles into nanoparticles in aqueous solution and transforms into nanofibers upon specific binding to HER2 on cancer cells. This transformation disrupts HER2 dimerization and subsequent downstream signaling events, leading to cancer cell apoptosis (Apoptosis) . The inhibitory effects on HER2 positive breast cancer have been demonstrated to be effective in a murine xenograft model[1].

• CAS Number :

  [535959-77-4]

• UNSPSC :

  12352209

• Target :

  Apoptosis; EGFR

• Related Pathways :

  Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Smiles :

  O=C(N[C@@H](CSSC[C@@H](C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CCSC)C(N[C@@H](CC(O)=O)C(N[C@@H](C(C)C)C(O)=O)=O)=O)=O)=O)NC2=O)C(N[C@@H](CC(O)=O)C(NCC(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CC4=CC=C(C=C4)O)C(N[C@H]2C)=O)=O)=O)=O)=O)[C@H](CC5=CC=C(C=C5)O)N

• Molecular Formula :

  C65H82N12O20S3

• Molecular Weight :

  1447.61

• References & Citations :

  [1]Zhang L, et al. Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo. Nat Nanotechnol. 2020 Feb;15 (2) :145-153.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Peptides

• Clinical Information :

  No Development Reported

• Isoform :

  ErbB2/HER2